Biotechniques
BioTechniques is a London-based scientific publisher (founded 1983, 51–100 employees) producing methods, protocols, and techniques content for biotech researchers, extended via the Future Medicine platform into video, articles, events coverage, and a £2.99/month consumer membership.
- Company typePrivate
- Founded1983
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingDigital Commerce or Content
What Biotechniques does
BioTechniques is a specialist scientific publishing platform founded in 1983 and headquartered in London, United Kingdom, employing 51–100 people. The firm publishes original methods, tools, protocols, and techniques-oriented articles for the biotechnology research community, operating from the future-science.com domain under the Future Science Group umbrella. Its editorial scope includes coverage of emerging laboratory methods — for example, the journal featured connectomics (electron microscopy combined with AI for brain mapping), which Nature named Method of the Year for 2025, including a mouse visual cortex connectome of over 200,000 cells and 523 million synapses.
The associated Future Medicine platform extends the business beyond traditional journal publishing into a multi-format healthcare media ecosystem. It comprises four core content pillars: Future Medicine TV (a creator-led video platform with at least eight show series hosted by named academic and clinical figures covering AI in healthcare, neurotech, digital eye health, surgery, and mental health), Deep Dives (written articles), Events (conference coverage spanning Digital Health Rewired, Giant Health, The Surgeon Show, and others), and Profiles (company and innovator spotlights). Content is distributed globally via the futuremedicine.com website and active LinkedIn, YouTube, Instagram, and X channels.
The revenue model centers on a consumer subscription membership priced at £2.99 per month after a 30-day free trial, supplemented by likely advertising, event sponsorship, and any institutional journal licensing (not disclosed in the source data). No revenue figures, subscriber counts, funding history, or enterprise customer logos are disclosed, and ownership or parent-company structure is not characterized in the available sources beyond the future-science.com domain association.
Biotechniques firmographics
Firmographics- Name
- Biotechniques
- Website
- https://future-science.com
- Company type
- Private
- Founded year
- 1983
- Headcount range
- 51–100 employees
- Short description
- BioTechniques is a London-based scientific publisher (founded 1983, 51–100 employees) producing methods, protocols, and techniques content for biotech researchers, extended via the Future Medicine platform into video, articles, events coverage, and a £2.99/month consumer membership.
- Ownership category
- akta.pro rank
Biotechniques industry classification
Industry- Product category
- Healthcare Media and Scientific Publishing
- NAICS
- Media Streaming Distribution Services, Social Networks, and Other Media Networks and Content Providers (51621)
- akta.pro primary industry
- Medical & Clinical Reference (Physicians, Nursing, Allied Health) (EDAGAGAA)
- akta.pro secondary industry
- Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ)
Keywords
Where Biotechniques is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Biotechniques business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Distribution channels1 record
Marketing channels4 records
Biotechniques product offering
Product offeringCore offering
BioTechniques operates a multi-platform healthcare content media brand (Future Medicine) that publishes creator-led video shows, in-depth written articles (Deep Dives), industry event coverage, and innovator/company profiles. The platform aggregates expert insights from named healthcare thought leaders and professors across topics including AI in healthcare, digital health, neurotechnology, robotics, surgery, and personalized medicine, with access gated behind a paid membership (£2.99/month after a 30-day free trial).
Product overview
Future Medicine is a multi-platform healthcare content media company offering a unified content ecosystem comprising Future Medicine TV (video shows), Deep Dives (articles), Events (conference coverage), and Profiles (company spotlights). The platform features multiple show series hosted by healthcare thought leaders covering topics including AI in healthcare, digital health, neurotechnology, robotics, surgery, and personalized medicine. Content is available via subscription membership at £2.99/month after a free trial.
Differentiator
Problem solved
Functional benefit
Products and services
- Future Medicine TV A creator-led video platform where healthcare's leading minds share unfiltered insights under studio lights, covering AI, digital health, neurotech, surgery, and mental health. Targeted at healthcare professionals and industry stakeholders.
- Deep Dives Long-form written articles providing in-depth analysis of important developments in medicine, including opinion pieces, company spotlights, and technology reviews (e.g., HealthTech, NHS AI, robotics in surgery, BioTechX content). Targeted at healthcare professionals seeking analysis below the surface of medical developments.
- Events Event coverage section providing rich insights from top healthcare industry events including Digital Health Rewired, The Surgeon Show, Giant Health, and Answer Digital. Targeted at healthcare professionals who cannot attend events in person.
- Profiles Company and innovator profile spotlights showcasing technologies transforming healthcare, including features on VitVio (surgical workflow), Nucleome Therapeutics (drug discovery), Holly Health (personalized health coaching), and Deep Medical. Targeted at healthcare professionals and industry stakeholders tracking emerging innovators.
- Future Medicine Membership Subscription membership providing access to Future Medicine's full content ecosystem (Future Medicine TV, Deep Dives, Events, Profiles). Priced at £2.99 per month after a 30-day free trial. Targeted at healthcare professionals and industry stakeholders.
Quantifiable outcome
- First complete connectomes of organisms including C. elegans, Drosophila, and mammalian brain sample
Companies that use Biotechniques
Customer profileIdeal customer profiles1 record
Biotechniques technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature1 record
Biotechniques partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights4 records
Biotechniques competitors and assessment
Company assessmentDirect peers
- Current Protocols: Wiley's long-running protocols reference library covering molecular biology, bioinformatics, immunology and related fields. Comparable to BioTechniques as a recurring-updated methods reference for bench scientists.
- Bio-protocol: Open-access peer-reviewed protocol repository for life-science researchers. Direct competitor to BioTechniques' core journal content on detailed step-by-step experimental procedures.
- JoVE: Peer-reviewed video methods journal serving life-science researchers with visual protocols. Comparable to BioTechniques' journal plus the Future Medicine TV video layer combined.
- Nature Protocols: Step-by-step protocols journal from Springer Nature. Closely comparable to BioTechniques in both content type (detailed laboratory methods) and target reader (working life-science researchers).
- Nature Methods: Springer Nature's flagship methods journal publishing novel experimental techniques in the life sciences. Directly comparable to BioTechniques as a peer-reviewed methods/protocols publication serving the same bench-researcher audience.
- Methods (Elsevier journal): Elsevier's methods-focused journal publishing original methodology across molecular biology, biochemistry, and analytical chemistry. Comparable niche positioning to BioTechniques.
Broad incumbents
- Doximity: Largest U.S. professional network for physicians with a content/news layer. Comparable to Future Medicine as a subscription-supported platform monetizing HCP audience attention, though anchored on networking rather than editorial video.
- STAT News: Boston Globe Media's health and life-sciences news outlet serving HCPs, researchers, and industry. Comparable to Future Medicine as a subscription-supported healthcare content brand, though at significantly larger scale and broader editorial scope.
Emerging players
- Healthcare IT News: HIMSS Media publication covering health-IT, EHR, and digital transformation. Comparable to Future Medicine's AI/NHS/robotics coverage as B2B healthcare technology media targeting digital health decision makers.
- MedCity News: B2B news and events platform covering digital health, biotech, and health-tech innovation. Comparable to the Future Medicine Events and Profiles sections in audience (innovation-focused healthcare decision makers) and content format.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Biotechniques social profiles
Digital presenceBiotechniques financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biotechniques leadership team
Management profileNumber of profiles
Biotechniques funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biotechniques M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biotechniques
What does Biotechniques do?
BioTechniques operates a multi-platform healthcare content media brand (Future Medicine) that publishes creator-led video shows, in-depth written articles (Deep Dives), industry event coverage, and innovator/company profiles. The platform aggregates expert insights from named healthcare thought leaders and professors across topics including AI in healthcare, digital health, neurotechnology, robotics, surgery, and personalized medicine, with access gated behind a paid membership (£2.99/month after a 30-day free trial).
When was Biotechniques founded?
Biotechniques was founded in 1983. It employs 51 to 100 people.
Where is Biotechniques based?
Biotechniques is headquartered in London, United Kingdom, in the Europe region.
Who are Biotechniques's main competitors?
Direct peers on record are Current Protocols, Bio-protocol, JoVE, Nature Protocols, Nature Methods and Methods (Elsevier journal). Broad incumbents are Doximity and STAT News. Emerging players are Healthcare IT News and MedCity News.
Does Biotechniques have an API?
No public API is recorded for Biotechniques.
What industry is Biotechniques in?
Biotechniques's product category is Healthcare Media and Scientific Publishing. Its primary akta.pro industry code is EDAGAGAA, Medical & Clinical Reference (Physicians, Nursing, Allied Health), with a secondary code of EDAGANAJ, Healthcare & Clinical Professional Development (CME/CE). Its NAICS code is 51621.